U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Unknown
149124
Substance Class Protein
Created
by admin
on Wed Apr 02 11:06:34 GMT 2025
Edited
by admin
on Wed Apr 02 11:06:34 GMT 2025
Protein Type BISPECIFIC ANTIBODY
Protein Sub Type
Sequence Origin HUMAN
Sequence Type COMPLETE
Record UNII
X3U67W8G5W
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Pamvatamig
INN  
Official Name English
MCLA-129
Preferred Name English
Immunoglobulin G1-kappa, anti-[Homo sapiens MET (met proto-oncogene, hepatocyte growth factor (HGF) receptor, HGFR, scatter factor (SF) receptor, HGF/SF receptor, receptor tyrosine-protein kinase c-met, papillary renal cell carcinoma 2, RCCP2)] and anti-
Common Name English
pamvatamig [INN]
Common Name English
Gamma1 heavy chain anti-MET Homo sapiens (1-452)[VH (Homo sapiens IGHV7-4-1*02 (95.9%) -(IGHD) -IGHJ5*02 (100%), CDR-IMGT [8.8.16] (26-33.51-58.97-112)) (1-123)-Homo sapiens IGHG1*03, G1m3, nG1m1CH1 R120, E12, M14, G1v72 CH3 D7, E24 (CH1 R120(220) (124-2
Common Name English
Immunoglobulin G1 [357-aspartic acid,374-glutamic acid,de-C-terminal-lysine], anti-(human hepatocyte growth factor receptor c-Met) (human monoclonal MCLA-129 ?1-chain), disulfide with human monoclonal MCLA-129 ?-chain, (232?231?),(235?234?)-bis(disulfide
Common Name English
Code System Code Type Description
SMS_ID
300000031918
Created by admin on Wed Apr 02 11:06:34 GMT 2025 , Edited by admin on Wed Apr 02 11:06:34 GMT 2025
PRIMARY
CAS
2750004-05-6
Created by admin on Wed Apr 02 11:06:34 GMT 2025 , Edited by admin on Wed Apr 02 11:06:34 GMT 2025
PRIMARY
NCI_THESAURUS
C179831
Created by admin on Wed Apr 02 11:06:34 GMT 2025 , Edited by admin on Wed Apr 02 11:06:34 GMT 2025
PRIMARY
INN
12549
Created by admin on Wed Apr 02 11:06:34 GMT 2025 , Edited by admin on Wed Apr 02 11:06:34 GMT 2025
PRIMARY
FDA UNII
X3U67W8G5W
Created by admin on Wed Apr 02 11:06:34 GMT 2025 , Edited by admin on Wed Apr 02 11:06:34 GMT 2025
PRIMARY
From To
4_134 4_194
4_23 4_88
3_134 3_194
3_23 3_88
2_372 2_430
2_266 2_326
2_225 4_214
2_149 2_205
2_22 2_96
1_226 3_214
1_373 1_431
1_267 1_327
1_235 2_234
1_232 2_231
1_150 1_206
1_22 1_96
Glycosylation Link Type Site
N 1_303
N 2_302
Related Record Type Details
EPIDERMAL GROWTH FACTOR RECEPTOR
TARGET -> INHIBITOR
IN-VIVO
HEPATOCYTE GROWTH FACTOR RECEPTOR
TARGET -> INHIBITOR
IN-VIVO
Related Record Type Details
Pamvatamig
ACTIVE MOIETY
Antibody-dependent cell cytotoxicity

Structural Modifications

Modification Type Location Site Location Type Residue Modified Extent Fragment Name Fragment Approval
AMINO_ACID_SUBSTITUTION [1_1] [2_1] PIDOLIC ACID SZB83O1W42
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
Molecular Formula CHEMICAL
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966